CureMatch, Inc.

CureMatch, Inc. utilizes advanced algorithms to provide oncologists with predictive treatment analyses tailored to individual cancer patients, enhancing personalized medicine through innovative therapy matching solutions. CureMatch, Inc. specializes in personalized cancer treatment by offering a sophisticated Decision Support System that analyzes molecular tumor profiles.

Founded in 2015, the company operates from San Diego, US. The founders include Blaise Barrelet, Navid Alipour, and Razelle Kurzrock, with Navid Alipour currently serving as CEO. In August 2017, the company secured Series A funding led by Serra Ventures, with individual investor Phil Trubey participating. To date, CureMatch has completed 2 funding deals, with the latest occurring on 2017-08-18.

CureMatch, Inc. provides a sophisticated Decision Support System that utilizes advanced algorithms to offer oncologists predictive treatment analyses tailored to individual cancer patients based on their molecular tumor profiles. The core service revolves around their therapy matching and scoring system, which ranks and scores combination drug therapies specifically targeting a patient’s genomic data, regardless of the cancer type diagnosed. This service is designed to help oncologists select optimal treatment options, thereby increasing progression-free survival rates for patients.

The primary clientele consists of oncologists, cancer centers, next-generation sequencing (NGS) laboratories, and concierge medicine providers, who rely on CureMatch's actionable insights to improve patient outcomes. The company’s offerings are primarily available in the United States, with ongoing efforts to expand its reach into additional international markets where personalized cancer treatment is gaining traction. CureMatch operates on a B2B model, primarily generating revenue through partnerships with healthcare providers and institutions that utilize its therapy matching services. The transactions typically involve healthcare facilities subscribing to CureMatch's services, allowing oncologists to access tailored treatment analyses for their patients.

This partnership structure enables oncologists to leverage the proprietary algorithms to enhance their decision-making capabilities in cancer treatment. CureMatch's services include a therapy matching system that was recently granted a Category III CPT code, facilitating reimbursement processes for oncologists integrating these services into their practices. Specific pricing plans and detailed transaction structures remain undisclosed; however, the revenue model operates on a subscription basis that ensures ongoing access to the technology and support services offered by CureMatch. CureMatch plans to leverage its recent Series A funding from August 2017 to enhance its technology and expand its offerings.

The company is focusing on developing new products that enhance its therapy matching capabilities, with plans to potentially release updates within the next year. Furthermore, CureMatch aims to extend its services into additional international markets, particularly in regions where personalized cancer treatments are gaining prominence, with targeted expansion efforts expected over the next two years.